JP6951826B2 - ヒト化抗ｃｄ３抗体、その複合体、およびその使用 - Google Patents

ヒト化抗ｃｄ３抗体、その複合体、およびその使用 Download PDF

Info

Publication number
JP6951826B2
JP6951826B2 JP2018539317A JP2018539317A JP6951826B2 JP 6951826 B2 JP6951826 B2 JP 6951826B2 JP 2018539317 A JP2018539317 A JP 2018539317A JP 2018539317 A JP2018539317 A JP 2018539317A JP 6951826 B2 JP6951826 B2 JP 6951826B2
Authority
JP
Japan
Prior art keywords
amino acid
antibody
acid sequence
seq
sequence comprises
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018539317A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019512002A5 (enExample
JP2019512002A (ja
Inventor
キム，チャンヒョク
ヤング，トラヴィス
キム，ミンスー
マ，ジェニファー
プレスタ，レオナルド
ジー． シュルツ，ピーター
ジー． シュルツ，ピーター
Original Assignee
ザ スクリプス リサーチ インスティテュート
ザ スクリプス リサーチ インスティテュート
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ザ スクリプス リサーチ インスティテュート, ザ スクリプス リサーチ インスティテュート filed Critical ザ スクリプス リサーチ インスティテュート
Publication of JP2019512002A publication Critical patent/JP2019512002A/ja
Publication of JP2019512002A5 publication Critical patent/JP2019512002A5/ja
Priority to JP2021153453A priority Critical patent/JP2022023052A/ja
Application granted granted Critical
Publication of JP6951826B2 publication Critical patent/JP6951826B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6869—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from a cell of the reproductive system: ovaria, uterus, testes, prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Reproductive Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2018539317A 2016-02-04 2017-02-03 ヒト化抗ｃｄ３抗体、その複合体、およびその使用 Active JP6951826B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2021153453A JP2022023052A (ja) 2016-02-04 2021-09-21 ヒト化抗ｃｄ３抗体、その複合体、およびその使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662291143P 2016-02-04 2016-02-04
US62/291,143 2016-02-04
PCT/US2017/016407 WO2017136659A2 (en) 2016-02-04 2017-02-03 Humanized anti-cd3 antibodies, conjugates and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021153453A Division JP2022023052A (ja) 2016-02-04 2021-09-21 ヒト化抗ｃｄ３抗体、その複合体、およびその使用

Publications (3)

Publication Number Publication Date
JP2019512002A JP2019512002A (ja) 2019-05-09
JP2019512002A5 JP2019512002A5 (enExample) 2020-03-26
JP6951826B2 true JP6951826B2 (ja) 2021-10-20

Family

ID=59501004

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2018539317A Active JP6951826B2 (ja) 2016-02-04 2017-02-03 ヒト化抗ｃｄ３抗体、その複合体、およびその使用
JP2021153453A Pending JP2022023052A (ja) 2016-02-04 2021-09-21 ヒト化抗ｃｄ３抗体、その複合体、およびその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2021153453A Pending JP2022023052A (ja) 2016-02-04 2021-09-21 ヒト化抗ｃｄ３抗体、その複合体、およびその使用

Country Status (9)

Country Link
US (1) US12252534B2 (enExample)
EP (1) EP3411069B1 (enExample)
JP (2) JP6951826B2 (enExample)
KR (1) KR102891788B1 (enExample)
CN (1) CN109069635B (enExample)
AU (1) AU2017213886B2 (enExample)
CA (1) CA3013463C (enExample)
ES (1) ES2992761T3 (enExample)
WO (1) WO2017136659A2 (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160017058A1 (en) 2013-03-14 2016-01-21 The California Institute For Biomedical Research Bispecific antibodies and uses thereof
US12252534B2 (en) 2016-02-04 2025-03-18 The Scripps Research Institute Humanized anti-CD3 antibodies, conjugates and uses thereof
US11472880B2 (en) 2017-08-14 2022-10-18 Morphosys Ag Humanized antibodies for CD3
KR101973060B1 (ko) * 2017-10-20 2019-04-26 주식회사 녹십자 항-cd3 항체 및 이를 포함하는 암 치료용 약학적 조성물
EP3844188A1 (en) * 2018-08-28 2021-07-07 Ambrx, Inc. Anti-cd3 antibody folate bioconjugates and their uses
US20220089722A1 (en) * 2018-12-29 2022-03-24 Nantong Yichen Biopharma. Co. Ltd. Heterodimeric fusion protein
CA3131036A1 (en) * 2019-02-22 2020-08-27 Wuhan Yzy Biopharma Co., Ltd. Cd3 antigen-binding fragment and application thereof
US20200392230A1 (en) * 2019-05-14 2020-12-17 Qlb Biotherapeutics Bispecific anti-cd3 x cd20 antibodies and uses thereof
UY38701A (es) 2019-05-21 2020-12-31 Novartis Ag Moléculas de unión a cd19, conjugados, composiciones que las comprenden y usos de las mismas
AU2020279224B2 (en) 2019-05-21 2024-12-05 Novartis Ag Trispecific binding molecules against BCMA and uses thereof
TWI841790B (zh) * 2019-09-30 2024-05-11 大陸商和鉑醫藥（上海）有限責任公司 靶向cd3的抗體、雙特異性抗體及其用途
CN113677704B (zh) * 2019-11-22 2024-03-26 南通壹宸生物医药科技有限公司 Psma抗体及其应用
WO2021173889A1 (en) 2020-02-26 2021-09-02 Ambrx, Inc. Uses of anti-cd3 antibody folate bioconjugates
TWI827807B (zh) * 2020-02-26 2024-01-01 香港商潤俊（中國）有限公司 抗cd3抗體葉酸生物共軛物及其用途
JP7518286B2 (ja) 2020-08-25 2024-07-17 ギリアード サイエンシーズ， インコーポレイテッド Ｈｉｖを標的とする多重特異性抗原結合分子及び使用方法
CN114853897B (zh) * 2021-04-15 2024-01-26 北京大学深圳研究生院 抗cd19/cd22/cd3三特异性抗体及用途
EP4384218A4 (en) * 2021-08-09 2025-11-05 Merck Patent Gmbh Proteins that uncouple T-lymphocyte-mediated tumor cytotoxicity from the release of pro-inflammatory cytokines
IL314993A (en) 2022-02-23 2024-10-01 Xencor Inc Anti-cd28 x anti-psma antibodies
CN120603604A (zh) * 2022-11-18 2025-09-05 Jn生物科学有限责任公司 抗cd3抗体
WO2024112867A1 (en) 2022-11-23 2024-05-30 University Of Georgia Research Foundation, Inc. Compositions and methods of use thereof for increasing immune responses
KR20240139569A (ko) * 2023-03-13 2024-09-23 머스트바이오 주식회사 신규한 cd3 결합항체 및 이를 포함한 다중특이 항체
CN121135889A (zh) * 2024-06-13 2025-12-16 合肥天港免疫药物有限公司 靶向b7h7和cd3的双特异性抗体及其应用
US20260209367A1 (en) 2024-11-22 2026-07-23 Gilead Sciences, Inc. SINGLE IMMUNOGLOBULIN DOMAIN BISPECIFIC ANTIBODIES AGAINST IL 10R alpha AND beta SUBUNITS AND METHODS OF USE

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
US5258498A (en) 1987-05-21 1993-11-02 Creative Biomolecules, Inc. Polypeptide linkers for production of biosynthetic proteins
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
WO1993011794A1 (en) 1991-12-13 1993-06-24 Xoma Corporation Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof
WO1999029888A1 (en) 1997-12-05 1999-06-17 The Scripps Research Institute Humanization of murine antibody
US20020142000A1 (en) 1999-01-15 2002-10-03 Digan Mary Ellen Anti-CD3 immunotoxins and therapeutic uses therefor
US6256533B1 (en) 1999-06-09 2001-07-03 The Procter & Gamble Company Apparatus and method for using an intracutaneous microneedle array
BR0212897A (pt) 2001-09-21 2004-08-24 Univ Tulane Conjugados de análogos de somatostatina ou bombesina diagnóstica ou terapêutica e usos dos mesmos
US7122622B2 (en) 2002-04-16 2006-10-17 Biosynthema Inc. Peptide compounds having improved binding affinity to somatostatin receptors
AU2004242845B2 (en) 2003-05-31 2011-06-02 Amgen Research (Munich) Gmbh Human-anti-human CD3 binding molecules
US8574533B2 (en) 2004-03-30 2013-11-05 Kureha Corporation Material for negative electrode of non-aqueous electrolyte secondary battery, process for producing the same, negative electrode and battery
CN1961003B (zh) 2004-03-31 2013-03-27 健泰科生物技术公司 人源化抗TGF-β抗体
US8236308B2 (en) 2005-10-11 2012-08-07 Micromet Ag Composition comprising cross-species-specific antibodies and uses thereof
WO2007058725A2 (en) * 2005-10-12 2007-05-24 The Regents Of The University Of California Engineered antibody fragment that irreversibly binds an antigen
EP1951890A4 (en) 2005-11-16 2009-06-24 Ambrx Inc PROCESSES AND COMPOSITIONS WITH NON-NATURAL AMINO ACIDS
KR101423898B1 (ko) 2005-12-14 2014-07-28 암브룩스, 인코포레이티드 비-천연 아미노산 및 폴리펩티드를 함유하는 조성물, 비-천연 아미노산 및 폴리펩티드를 포함하는 방법, 및 비-천연 아미노산 및 폴리펩티드의 용도
AU2006332809A1 (en) 2005-12-30 2007-07-12 Ambrx, Inc. Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides
AU2007215566A1 (en) 2006-01-19 2007-08-23 Ambrx, Inc. Non-natural amino acid polypeptides having modulated immunogenicity
AU2007333737A1 (en) 2006-12-18 2008-06-26 Ambrx, Inc. Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides
US20100098630A1 (en) 2006-12-28 2010-04-22 Ambrx, Inc. Phenazine and Quinoxaline Substituted Amino Acids and Polypeptides
DK2187965T3 (da) 2007-08-17 2020-01-20 Purdue Research Foundation Psma-bindingsligand-linker-konjugater og fremgangsmåder til anvendelse
US8536310B2 (en) 2007-10-17 2013-09-17 Arca Biopharma, Inc. Antibodies to CLL-1
EP2225275A4 (en) 2007-11-28 2013-04-03 Medimmune Llc PROTEIN FORMULATION
HRP20151367T1 (hr) 2008-05-13 2016-01-29 Yale University Kimerne male molekule za pojaäśanje odgovora protutijela na stanice raka
PE20110480A1 (es) 2008-09-26 2011-07-01 Ambrx Inc Microorganismos y vacunas dependientes de replicacion de aminoacidos no naturales
US20120189621A1 (en) * 2011-01-21 2012-07-26 Yann Dean Combination Therapies and Methods Using Anti-CD3 Modulating Agents and Anti-IL-6 Antagonists
WO2012142659A1 (en) 2011-04-19 2012-10-26 Baker Idi Heart And Diabetes Institute Holdings Limited Site-selective modification of proteins
WO2012162067A2 (en) * 2011-05-21 2012-11-29 Macrogenics, Inc. Cd3-binding molecules capable of binding to human and non-human cd3
KR20200128601A (ko) 2011-05-27 2020-11-13 암브룩스, 인코포레이티드 비-천연 아미노산 연결된 돌라스타틴 유도체를 함유하는 조성물, 이를 수반하는 방법, 및 용도
DK2714685T3 (en) 2011-05-27 2017-01-09 Ambrx Inc FORMATIONS CONTAINING, METHODS INVOLVING, AND USES OF NON-NATURAL AMINO ACID BOUND dolastatin
US10851178B2 (en) 2011-10-10 2020-12-01 Xencor, Inc. Heterodimeric human IgG1 polypeptides with isoelectric point modifications
EP3539982B1 (en) 2011-12-23 2025-02-19 Pfizer Inc. Engineered antibody constant regions for site-specific conjugation and methods and uses therefor
BR112015006824A2 (pt) 2012-09-27 2017-07-04 Merus B V anticorpo igg biespecífico, método para produzir um anticorpo igg biespecífico, anticorpo, composição farmacêutica e uso de um anticorpo igg biespecífico
MX2015003616A (es) 2012-10-08 2015-06-05 Roche Glycart Ag Anticuerpos sin fc que comprenden dos fragmentos fab y metodos de uso.
US9273093B2 (en) 2012-10-11 2016-03-01 Protagonist Therapeutics, Inc. α4β7 peptide dimer antagonists
US10131710B2 (en) 2013-01-14 2018-11-20 Xencor, Inc. Optimized antibody variable regions
US9605084B2 (en) 2013-03-15 2017-03-28 Xencor, Inc. Heterodimeric proteins
CN104936985A (zh) 2013-02-26 2015-09-23 罗切格利卡特公司 双特异性t细胞活化性抗原结合分子
US20160017058A1 (en) 2013-03-14 2016-01-21 The California Institute For Biomedical Research Bispecific antibodies and uses thereof
WO2014185985A1 (en) 2013-05-14 2014-11-20 Ambrx, Inc. Novel polypeptide small molecule conjugates and their uses
ES2648094T3 (es) 2013-06-07 2017-12-28 Rhizen Pharmaceuticals S.A. Inhibidores de PI3 cinasa delta y gamma selectivos duales
AU2014337385B2 (en) * 2013-10-15 2020-04-30 The Scripps Research Institute Chimeric antigen receptor T cell switches and uses thereof
AP2016009222A0 (en) 2013-11-04 2016-05-31 Glenmark Pharmaceuticals Sa Production of t cell retargeting hetero-dimeric immunoglobulins
HUE050159T2 (hu) * 2013-12-17 2020-11-30 Genentech Inc Anti-CD3 antitestek és alkalmazási eljárások
US10647768B2 (en) 2014-05-29 2020-05-12 Macrogenics, Inc. Multi-chain polypeptide-containing tri-specific binding molecules
CA2955947A1 (en) * 2014-07-25 2016-01-28 Cytomx Therapeutics, Inc. Anti-cd3 antibodies, activatable anti-cd3 antibodies, multispecific anti-cd3 antibodies, multispecific activatable anti-cd3 antibodies, and methods of using the same
US11091546B2 (en) 2015-04-15 2021-08-17 The Scripps Research Institute Optimized PNE-based chimeric receptor T cell switches and uses thereof
US12252534B2 (en) 2016-02-04 2025-03-18 The Scripps Research Institute Humanized anti-CD3 antibodies, conjugates and uses thereof

Also Published As

Publication number Publication date
JP2022023052A (ja) 2022-02-07
CN109069635B (zh) 2023-09-26
AU2017213886A1 (en) 2018-08-16
EP3411069A2 (en) 2018-12-12
US20230192844A1 (en) 2023-06-22
AU2017213886B2 (en) 2024-03-07
JP2019512002A (ja) 2019-05-09
ES2992761T3 (en) 2024-12-17
US12252534B2 (en) 2025-03-18
CA3013463C (en) 2024-05-21
KR102891788B1 (ko) 2025-11-26
KR20180104157A (ko) 2018-09-19
CN109069635A (zh) 2018-12-21
EP3411069A4 (en) 2020-02-19
EP3411069B1 (en) 2024-07-10
CA3013463A1 (en) 2017-08-10
WO2017136659A2 (en) 2017-08-10
WO2017136659A3 (en) 2017-09-08

Similar Documents

Publication Publication Date Title
JP2022023052A (ja) ヒト化抗ｃｄ３抗体、その複合体、およびその使用
TWI815815B (zh) Bcma單株抗體-藥物結合物
US12377163B2 (en) Anti-B7H3 antibody-exatecan analog conjugate and medicinal use thereof
JP2025060760A (ja) アマトキシン抗体薬物複合体及びその使用
JP7042876B2 (ja) Ｃｙｓ８０抱合型免疫グロブリン
TWI904109B (zh) 抗ｃｄ４５抗體及其結合物
JP2025508009A (ja) ＦＲαに対する結合分子
CA3166139C (en) Engineered anti-il-2 antibodies
TW201832778A (zh) 對ａｓｃｔ２具有特異性的結合分子及其用途
BR112021003843A2 (pt) biconjugados de folato de anticorpo anti-cd3 e seus usos
JP7762294B2 (ja) 抗ｃｄ３９抗体ー薬物複合体及びその使用
JP2024544757A (ja) タンパク質複合体の組成物およびその使用方法
WO2021173889A1 (en) Uses of anti-cd3 antibody folate bioconjugates
TW202417054A (zh) 配體－細胞毒性藥物偶聯物及其藥物用途
HK40000405A (en) Humanized anti-cd3 antibodies, conjugates and uses thereof
HK40000405B (en) Humanized anti-cd3 antibodies, conjugates and uses thereof
JP2025088767A (ja) ＰＳＭＡ－ＳＴＥＡＰ１二重可変ドメイン免疫グロブリン（ＤＶＤ－Ｉｇ）分子及び薬物コンジュゲート
TW202604959A (zh) 抗EGFR×cMet雙特異性抗體的藥物偶聯物及其用途
JP2026506049A (ja) 治療用結合分子を用いた癌の治療のための併用療法
HK40094038A (en) Antibody drug conjugates

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181210

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200130

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200130

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20200227

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200309

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210105

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210402

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20210901

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20210924

R150 Certificate of patent or registration of utility model

Ref document number: 6951826

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250